
Keith Croes
Contributing Writer
- All
- Deals
- Devices and Diagnostics
- Digital
- Genetics
- Pharma
CRISPR and inherited retinal disease
Once again the eye proved to be the pioneer target in a new gene therapy approach, with the use in February of an agent utilizing ...
Read More AbbVie and Allergan Are Going to Be Just Fine
Media coverage of AbbVie’s (NYSE: ABBV) acquisition of Allergan (NYSE: AGN) in June was both bullish and bearish. In our initial coverage, we took a ...
Read More Soft CL slows myopia in children
Globally, the myopia market may be worth upwards of $28 billion by 2026, with single prescription corrective lenses holding a significant market share, according to ...
Read More Lucentis and Eylea patent expirations in the micro-crystal ball
Over the past 10 years, the Dow Jones Industrial Average has seen a 10-year climb with small calendar-year dips seen in 2015 (-2.23%) and 2018 ...
Read More RegenxBio sues FDA over clinical hold
Days after the U.S. Food and Drug Administration placed a partial hold on RGX-314, RegenxBio (NASDAQ: RGNX) lead gene therapy agent, the company initially outlined ...
Read More Opthea’s Star Brightens for Stakeholders
It’s been a good year for Opthea Ltd., a biotechnology company based in Melbourne, Australia. It’s listed on the Australian Securities Exchange (ASX), trading as ...
Read More Eyeing Gene Therapy’s Ocular Future
CHICAGO—The first gene therapy approved in the United States happened to be for an inherited eye disease, with an agent that is administered subretinally. But ...
Read More Retina Treatment Beyond Protocol
CHICAGO — Optimal treatment of retinal diseases hinges on better understanding in three primary areas, said an expert panel at OIS@ASRS 2019: the disease mechanisms ...
Read More A Closer Look at Glaukos’ Bid for Avedro
Early market reaction to Glaukos Corp.'s all-stock acquisition of Avedro Inc. was mixed; a decrease in stock price for Glaukos and an increase for Avedro. ...
Read More OIS@ASRS at the Ritz-Carlton Chicago: An In-depth Look at the Retina Space
CHICAGO – The extensive, intensive public and private investment in the retinal space will fill the day next Thursday, July 25, at the OIS@ASRS meeting, ...
Read More A Closer Look at AbbVie-Allergan Deal and Where Eye Care Fits In
NEW YORK – In what’s been called “a transformative move for both companies,” AbbVie has agreed to buy Allergan in a deal valued at $63 ...
Read More Why Equity and M&A Markets in Ophthalmology Are Poised for a Great Run
SAN DIEGO – Although the 10-year bull market is bound to end one of these days, the trend in ophthalmology and healthcare in general is ...
Read More